Education
About Us
Working with TipRanks
Follow Us
Avalo Therapeutics, Inc. (AVTX)
:AVTX
AVTX Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AVTX Stock 12 Month Forecast
Average Price Target
$15.00
▲(213.81%Upside)
| Highest Price Target$15.00 | Average Price Target$15.00 | Lowest Price Target$15.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$4.5
Hold
-5.86%
Downside
Reiterated
06/20/25
The overall stock score for Avalo Therapeutics is primarily impacted by significant financial challenges, including declining revenues and persistent losses. While technical and corporate event indicators provide some positive signals, the negative valuation metrics and financial instability weigh heavily on the overall score.
H.C. Wainwright
$15
Buy
213.81%
Upside
Initiated
06/02/25
Jefferies
$23
Buy
381.17%
Upside
Initiated
03/25/25
Stifel Nicolaus
$36
Buy
653.14%
Upside
Initiated
03/25/25
Oppenheimer
$35
Buy
632.22%
Upside
Reiterated
03/24/25
BTIG
$40
Buy
736.82%
Upside
Reiterated
03/20/25
Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS TreatmentWe view hidradenitis suppurativa (HS) as a high-growth opportunity (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s) where multiple commercially successful therapies can coexist, and we expect AVTX-009 to emerge as the best-in-class IL-1 inhibitor for the disease. Topline results from the ongoing in HS (LOTUS) are expected in 2026 (first patient enrolled October 2024) and we see high odds of AVTX-009's differentiating features (IL-1β potency and specificity, higher potency, better SC bioavailability, and longer half-life) translating into greater efficacy compared to lutikizumab. Beyond HS, mgmt. plans to announce a second indication to evaluate AVTX-009.
Piper Sandler
$48
Buy
904.18%
Upside
Reiterated
03/20/25
Wedbush
$18
Buy
276.57%
Upside
Initiated
02/20/25
Lucid Capital
$24
Buy
402.09%
Upside
Initiated
12/17/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$4.5
Hold
-5.86%
Downside
Reiterated
06/20/25
The overall stock score for Avalo Therapeutics is primarily impacted by significant financial challenges, including declining revenues and persistent losses. While technical and corporate event indicators provide some positive signals, the negative valuation metrics and financial instability weigh heavily on the overall score.
H.C. Wainwright
$15
Buy
213.81%
Upside
Initiated
06/02/25
Jefferies
$23
Buy
381.17%
Upside
Initiated
03/25/25
Stifel Nicolaus
$36
Buy
653.14%
Upside
Initiated
03/25/25
Oppenheimer
$35
Buy
632.22%
Upside
Reiterated
03/24/25
BTIG
$40
Buy
736.82%
Upside
Reiterated
03/20/25
Promising Investment Opportunity in Avalo Therapeutics: Strong Financial Position and Breakthrough HS TreatmentWe view hidradenitis suppurativa (HS) as a high-growth opportunity (US market size is expected to grow from ~$2B/yr today to >$10B/yr by the mid-2030s) where multiple commercially successful therapies can coexist, and we expect AVTX-009 to emerge as the best-in-class IL-1 inhibitor for the disease. Topline results from the ongoing in HS (LOTUS) are expected in 2026 (first patient enrolled October 2024) and we see high odds of AVTX-009's differentiating features (IL-1β potency and specificity, higher potency, better SC bioavailability, and longer half-life) translating into greater efficacy compared to lutikizumab. Beyond HS, mgmt. plans to announce a second indication to evaluate AVTX-009.
Piper Sandler
$48
Buy
904.18%
Upside
Reiterated
03/20/25
Wedbush
$18
Buy
276.57%
Upside
Initiated
02/20/25
Lucid Capital
$24
Buy
402.09%
Upside
Initiated
12/17/24
Best Analysts Covering Avalo Therapeutics
1 Month
xxx
Success Rate
8/19 ratings generated profit
Average Return
+0.72%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 42.11% of your transactions generating a profit, with an average return of +0.72% per trade.
3 Months
xxx
Success Rate
8/19 ratings generated profit
Average Return
-5.04%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -5.04% per trade.
1 Year
Success Rate
3/19 ratings generated profit
Average Return
-46.89%
reiterated a buy rating 3 months ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 15.79% of your transactions generating a profit, with an average return of -46.89% per trade.
2 Years
xxx
Success Rate
0/19 ratings generated profit
Average Return
-77.15%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -77.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AVTX Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Feb 25
Mar 25
Jun 25
Strong Buy
3
5
6
10
8
Buy
0
0
0
0
0
Hold
2
2
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
7
7
11
9
Each month's total comprises the sum of three months' worth of ratings.
AVTX Financial Forecast
AVTX Stock Forecast FAQ
What is AVTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Avalo Therapeutics, Inc.’s 12-month average price target is 15.00.
What is AVTX’s upside potential, based on the analysts’ average price target?
Avalo Therapeutics, Inc. has 213.81% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AVTX a Buy, Sell or Hold?
Avalo Therapeutics, Inc. has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Avalo Therapeutics, Inc.’s price target?
The average price target for Avalo Therapeutics, Inc. is 15.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $15.00. The average price target represents 213.81% Increase from the current price of $4.78.
The highest analyst price target is $15.00 ,the lowest forecast is $15.00. The average price target represents 213.81% Increase from the current price of $4.78.
What do analysts say about Avalo Therapeutics, Inc.?
Avalo Therapeutics, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of AVTX?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.